Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
18.3 USD | -2.50% | -0.87% | +34.56% |
Financials (USD)
Sales 2023 * | 137M | Sales 2024 * | 161M | Capitalization | 741M |
---|---|---|---|---|---|
Net income 2023 * | -43M | Net income 2024 * | -40M | EV / Sales 2023 * | 4,53x |
Net cash position 2023 * | 123M | Net cash position 2024 * | 104M | EV / Sales 2024 * | 3,96x |
P/E ratio 2023 * | -16,0x | P/E ratio 2024 * | -18,5x | Employees | 357 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | -2.50% | ||
1 week | -0.87% | ||
Current month | -3.48% | ||
1 month | +1.84% | ||
3 months | -19.06% | ||
6 months | -30.58% | ||
Current year | +34.56% |
1 week
17.88
19.19

1 month
15.57
19.19

Current year
12.44
29.51

1 year
11.23
29.51

3 years
11.14
37.21

5 years
7.20
37.21

10 years
7.20
37.21

Managers | Title | Age | Since |
---|---|---|---|
Laura A. Francis
CEO | Chief Executive Officer | 56 | 2015 |
Jeffrey W. Dunn
FOU | Founder | 68 | 2008 |
Director of Finance/CFO | 43 | 2021 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey W. Dunn
FOU | Founder | 68 | 2008 |
John Freund
BRD | Director/Board Member | 69 | 2012 |
Gregory Hinckley
BRD | Director/Board Member | 76 | 2010 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.09% | 277 M€ | -15.65% | - | |
0.70% | 108 M€ | -14.86% | ||
0.51% | 2 M€ | -.--% | - | |
0.46% | 5 M€ | -13.81% | ||
0.40% | 12 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-05 | 18.3 | -2.50% | 246,710 |
23-12-04 | 18.77 | -0.27% | 371,391 |
23-12-01 | 18.82 | -0.74% | 395,325 |
23-11-30 | 18.96 | +3.04% | 394,995 |
23-11-29 | 18.4 | +2.45% | 396,052 |
Delayed Quote Nasdaq, December 05, 2023 at 04:00 pm EST
More quotes
SI-BONE, Inc. is a medical device company. The Company is engaged in solving musculoskeletal disorders of the sacropelvic anatomy. The Company's products include a series of patented titanium implants and the instruments used to implant them. It offers iFuse, iFuse-3D, and iFuse-TORQ implant systems. iFuse is a machined triangular titanium implant that has a triangular cross-section that resists twisting or rotation of the implant. iFuse-3D implants are used for the fusion of the sacroiliac joint in conjunction with multi-level spinal fusion procedures to provide further stabilization and immobilization of the sacroiliac joint. iFuse-TORQ is a line of three-dimensional (3D)-printed threaded implants designed for use in pelvic trauma, as well as applications in sacroiliac joint dysfunction and degeneration. The Company also holds patents for the method of placing the implant across the sacroiliac joint, as well as other parts of the spine and pelvis.
Calendar
2024-03-05
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
BUY
Number of Analysts
7
Last Close Price
18.3USD
Average target price
25.62USD
Spread / Average Target
+40.03%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.56% | 760 M $ | |
-0.70% | 8 821 M $ | |
-14.23% | 6 572 M $ | |
+4.76% | 5 906 M $ | |
-31.46% | 5 357 M $ | |
+26.83% | 5 150 M $ | |
+4.52% | 4 679 M $ | |
+21.88% | 3 494 M $ | |
-29.04% | 2 439 M $ | |
-21.79% | 2 362 M $ |